Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?

Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was design...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilar, Lucio, Albuquerque, José Luciano, Gadelha, Patrícia Sampaio, Rangel Filho, Frederico, Siqueira, Aline Maria C., da Fonseca, Maíra Melo, Viana, Karoline Frazão, Gomes, Barbara Sales, Lyra, Ruy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316769/
https://www.ncbi.nlm.nih.gov/pubmed/25699020
http://dx.doi.org/10.3389/fendo.2015.00011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316769/
https://www.ncbi.nlm.nih.gov/pubmed/25699020
http://dx.doi.org/10.3389/fendo.2015.00011

Ejemplares similares